Clinical Trial

QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms

Name: QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms — clinical trial record (NCT07560449)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The purpose of the study is to compare the efficacy of QLS4131(SC) in combination with QL2109, with or without pomalidomide or lenalidomide, and QLS4131 (SC) in combination with QL2109, and QLS4131 (SC) in combination with Pomalidomide, and QLS4131(SC) in combination with QL2109 and Lenalidomide.

Trial Details

NCT Number	NCT07560449
Lead Sponsor	Qilu Pharmaceutical Co., Ltd.
Conditions	Malignant Plasma Cell Neoplasms
Enrollment	162 participants
Start Date	2026-06
Primary Completion	2028-06 (estimated)
Study Completion	2030-06 (estimated)
Updated on ClinicalTrials.gov	2026-05-01